vs
Side-by-side financial comparison of NORTHERN OIL & GAS, INC. (NOG) and Bio-Techne (TECH). Click either name above to swap in a different company.
NORTHERN OIL & GAS, INC. is the larger business by last-quarter revenue ($610.2M vs $311.4M, roughly 2.0× Bio-Techne). Bio-Techne runs the higher net margin — 16.4% vs -11.6%, a 28.0% gap on every dollar of revenue. On growth, Bio-Techne posted the faster year-over-year revenue change (-1.5% vs -72.6%). Over the past eight quarters, NORTHERN OIL & GAS, INC.'s revenue compounded faster (4.3% CAGR vs 1.3%).
Marathon Oil Corporation was an American company engaged in hydrocarbon exploration. In November 2024, it was acquired by ConocoPhillips and absorbed into the company.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
NOG vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $610.2M | $311.4M |
| Net Profit | $-70.7M | $51.0M |
| Gross Margin | — | 66.9% |
| Operating Margin | — | 24.2% |
| Net Margin | -11.6% | 16.4% |
| Revenue YoY | -72.6% | -1.5% |
| Net Profit YoY | -198.7% | 126.0% |
| EPS (diluted) | $-0.73 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $610.2M | $311.4M | ||
| Q4 25 | $610.2M | $295.9M | ||
| Q3 25 | $556.6M | — | ||
| Q2 25 | $706.8M | $317.0M | ||
| Q1 25 | $602.1M | $316.2M | ||
| Q4 24 | $515.0M | $297.0M | ||
| Q3 24 | $753.6M | $289.5M | ||
| Q2 24 | $560.8M | $306.1M |
| Q1 26 | $-70.7M | $51.0M | ||
| Q4 25 | $-70.7M | $38.0M | ||
| Q3 25 | $-129.1M | — | ||
| Q2 25 | $99.6M | $-17.7M | ||
| Q1 25 | $139.0M | $22.6M | ||
| Q4 24 | $71.7M | $34.9M | ||
| Q3 24 | $298.4M | $33.6M | ||
| Q2 24 | $138.6M | $40.6M |
| Q1 26 | — | 66.9% | ||
| Q4 25 | 80.4% | 64.6% | ||
| Q3 25 | 78.7% | — | ||
| Q2 25 | 82.8% | 62.7% | ||
| Q1 25 | 81.1% | 67.9% | ||
| Q4 24 | 77.4% | 65.3% | ||
| Q3 24 | 85.8% | 63.2% | ||
| Q2 24 | 82.0% | 66.4% |
| Q1 26 | — | 24.2% | ||
| Q4 25 | -5.5% | 18.4% | ||
| Q3 25 | -22.6% | — | ||
| Q2 25 | 24.9% | -7.5% | ||
| Q1 25 | 38.1% | 12.2% | ||
| Q4 24 | 25.8% | 16.0% | ||
| Q3 24 | 57.6% | 13.8% | ||
| Q2 24 | 39.0% | 15.0% |
| Q1 26 | -11.6% | 16.4% | ||
| Q4 25 | -11.6% | 12.8% | ||
| Q3 25 | -23.2% | — | ||
| Q2 25 | 14.1% | -5.6% | ||
| Q1 25 | 23.1% | 7.1% | ||
| Q4 24 | 13.9% | 11.7% | ||
| Q3 24 | 39.6% | 11.6% | ||
| Q2 24 | 24.7% | 13.3% |
| Q1 26 | $-0.73 | $0.32 | ||
| Q4 25 | $-0.67 | $0.24 | ||
| Q3 25 | $-1.33 | — | ||
| Q2 25 | $1.00 | $-0.11 | ||
| Q1 25 | $1.39 | $0.14 | ||
| Q4 24 | $0.71 | $0.22 | ||
| Q3 24 | $2.96 | $0.21 | ||
| Q2 24 | $1.36 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.3M | $209.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.1B | $2.1B |
| Total Assets | $5.4B | $2.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $14.3M | $209.8M | ||
| Q4 25 | $14.3M | $172.9M | ||
| Q3 25 | $31.6M | — | ||
| Q2 25 | $25.9M | $162.2M | ||
| Q1 25 | $33.6M | $140.7M | ||
| Q4 24 | $8.9M | $177.5M | ||
| Q3 24 | $34.4M | $187.5M | ||
| Q2 24 | $7.8M | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | $2.4B | $260.0M | ||
| Q3 25 | $2.3B | — | ||
| Q2 25 | $2.4B | $346.0M | ||
| Q1 25 | $2.3B | $330.0M | ||
| Q4 24 | $2.4B | $300.0M | ||
| Q3 24 | $2.0B | $300.0M | ||
| Q2 24 | $1.9B | $319.0M |
| Q1 26 | $2.1B | $2.1B | ||
| Q4 25 | $2.1B | $2.0B | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $2.4B | $1.9B | ||
| Q1 25 | $2.4B | $2.0B | ||
| Q4 24 | $2.3B | $2.1B | ||
| Q3 24 | $2.3B | $2.1B | ||
| Q2 24 | $2.1B | $2.1B |
| Q1 26 | $5.4B | $2.6B | ||
| Q4 25 | $5.4B | $2.5B | ||
| Q3 25 | $5.5B | — | ||
| Q2 25 | $5.7B | $2.6B | ||
| Q1 25 | $5.7B | $2.6B | ||
| Q4 24 | $5.6B | $2.7B | ||
| Q3 24 | $5.1B | $2.7B | ||
| Q2 24 | $4.7B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | 1.13× | 0.13× | ||
| Q3 25 | 1.05× | — | ||
| Q2 25 | 0.98× | 0.18× | ||
| Q1 25 | 0.96× | 0.16× | ||
| Q4 24 | 1.02× | 0.14× | ||
| Q3 24 | 0.84× | 0.14× | ||
| Q2 24 | 0.91× | 0.15× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $312.6M | — |
| Free Cash FlowOCF − Capex | $43.2M | — |
| FCF MarginFCF / Revenue | 7.1% | — |
| Capex IntensityCapex / Revenue | 31.5% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $312.6M | — | ||
| Q4 25 | $312.6M | — | ||
| Q3 25 | $423.1M | — | ||
| Q2 25 | $362.1M | $98.2M | ||
| Q1 25 | $407.4M | $41.1M | ||
| Q4 24 | $290.3M | $84.3M | ||
| Q3 24 | $385.8M | $63.9M | ||
| Q2 24 | $340.5M | $75.5M |
| Q1 26 | $43.2M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $93.3M | ||
| Q1 25 | — | $31.0M | ||
| Q4 24 | — | $77.5M | ||
| Q3 24 | — | $54.7M | ||
| Q2 24 | — | $57.5M |
| Q1 26 | 7.1% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 29.4% | ||
| Q1 25 | — | 9.8% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 18.9% | ||
| Q2 24 | — | 18.8% |
| Q1 26 | 31.5% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 3.2% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | — | 5.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 3.64× | — | ||
| Q1 25 | 2.93× | 1.82× | ||
| Q4 24 | 4.05× | 2.42× | ||
| Q3 24 | 1.29× | 1.90× | ||
| Q2 24 | 2.46× | 1.86× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NOG
| Oil and Gas Sales | $447.7M | 73% |
| Gain on Commodity Derivatives, Net | $159.3M | 26% |
| Other Revenue | $3.1M | 1% |
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
